  |
  |
Satellite Symposia
Sunday 3 september 2006
| 12.15 – 13.45 Satellite Symposium organised by OCD |
Room 1.61 – 1.64 |
| Global Automation and Process Excellence .... Today, Tomorrow and the Future |
|
| This event will highlight the benefits of full automation in the area of donor validation testing and patient pre-transfusion testing. It will also include customer presentations on ORTHO AutoVue® Innova and the new donor screening platform, the ORTHO Paradigm®, as well as a virtual reality tour through the donor screening laboratory of the future. | |
| AUTOMATION IN THE TRANSFUSION LABORATORY:10 YEAR EXPERIENCE | |
| J. Wallis (Freeman Hospital- Newcastle upon Tyne, United Kingdom) | |
| A MULTICENTRIC STUDY ON SECOND LEVEL AUTOMATION IN IMMUNOHEMATOLOGY | |
| M. Ripamonti (HTS Santa Chiara - Trento, Italy) | |
| THE DONOR CENTRE PERSPECTIVE | |
| K. Grundon (Automation Lead Engineer Ortho-Clincal Diagnostics) | |
| 12.15 – 13.45 Satellite Symposium organised by Pall Medical |
Room 1.41 – 1.44 |
| Prions in Transfusion Medicine | |
| Chair: A. Ross, Pall Corporation, USA | |
| VCJD AND BLOOD TRANSFUSION - INCIDENCE AND RISKS | |
| M. Turner (Scottish National Blood Transfusion Service, United Kingdom) | |
| PRION REDUCTION - THE FRENCH APPROACH | |
| J. Coste (Etablissements Français du Sanguine, Montpellier, France) | |
| FROM LEUKOCYTE DEPLETION TO PRION REDUCTION - EVOLVING STEPS TO INCREASE BLOOD SAFETY | |
| J. Ortalano (Pall Corporation, United States of America) | |
Monday 4 september 2006
| 12.15 – 13.45 Satellite Symposium organised by Gambro  |
Ballroom West |
| NEW IDEAS… NEW ENERGY | |
| (From one of the world’s foremost renaissance thinkers at the Gambro BCT satellite symposium) | |
| HOW TO THINK LIKE LEONARDO DA VINCI | |
| Seven steps to genius every day. Experience in the
energy and intelligence of innovation and creativity, expert ichael J. Gelb
(www.bigspeak.com). His entertaining seminar will teach you to: balance analysis and imagination; cultivate an innovative working environment; sustain continuous learning) |
|
| ISBT WORKING PARTY SYMPOSIUM | |
| 12.15 – 13.45 Symposium organised by ISBT Working Party on Transfusion Transmissible Diseases |
Ballroom East |
| Global experience with nucleic acid amplification (NAT) systems for blood donor screening | |
| Chairs: S. Wendel, K. Roth, M. Busch, J-P. Allain | |
| Part 1: Comparison of performance between two commercial IV/HCV/HBV NAT systems | |
| 12.00 – 12.10 | |
| P-128 COMPARISON OF THE CHIRON PROCLEIX® TIGRIS® AND OCHE COBAS S 201 NUCLEIC ACID TESTING (NAT) SYSTEMS FOR SIMULTANEOUS DETECTION OF HIV/HCV RNA AND HBV DNA * | |
| C.K. Lin, A.R. Margaritis, S. Brown, C.R. Seed, P. Kiely, B. D'Agostino, A.J. Keller (Australian Red Cross Blood Service, Perth, Australia) | |
| 12.10 – 12.20 | |
| P-108 HEAD TO HEAD COMPARISON OF TWO NEW AUTOMATED NAT SYSTEMS CHIRON: PROCLEIX TIGRIS SYSTEM VS ROCHE COBAS S 201 * | |
| A. Assal, V. Barlet, C. Cornillot, M. Deschazeaux, I. Dupont, P. Gallian, C. Guitton, P. Morel, G. Andreu (EFS Centre Atlantique, Tours, France) | |
| 12.20 – 12.30 | |
| DISCUSSION | |
| M.P. Busch (Blood Systems Research Institute, San Francisco, United States of America) | |
| Part 2: Feasibility and clinical yield of NAT in high prevalence areas | |
| 12.30 – 12.40 | |
| P-110 SEROLOGICAL AND MOLECULAR CHARACTERISTICS OF HBV DNA POSITIVE/ HBSAG NEGATIVE BLOOD DONORS * | |
| E. Brojer, M. Letowska, G. Liszewski, P. Grabarczyk, M. Mikulska (Institute of Haematology and Blood Transfusion, Warsaw, Poland) | |
| 12.40 – 12.50 | |
| P-018 DETECTION OF HIV-1 INFECTION IN BLOOD DONORS DURING THE IMMUNOLOGICAL WINDOW PERIOD BY IMPLEMENTATION OF NUCLEIC ACID AMPLIFICATION TECHNOLOGY * | |
| P.S.P. Scuracchio, A.G. Oliveira Filho, M.M.M. Lemos, M.C.C. Poli, R. Colella, M.M.C. Magri, N.J.F. Cavalcanti, E.C. Sabino, N.A. Salles, D.A.F. Chamone (Banco de Sangue de São Paulo, São Paulo, Brazil) | |
| 12.50 – 13.00 | |
| P-136 EVALUATION OF ACCEPTED BLOOD DONORS WITH A MULTIPLEX NUCLEIC ACID TEST (NAT) AT CHIANG MAI UNIVERSITY HOSPITAL, THAILAND * | |
| L.T. Thaikruea, N.N. Niwes, S.T. Thongsawat, L.N. Litrakoon, L.F. Fonksatidkil, P.S. Sompan, A.H. Heaton, D.N. Nichols, K.N. Nelson (Department of Community Medicine, Chiang Mai, Thailand) | |
| 13.00 – 13.10 | |
| P-106 IMPLEMENTATION OF A POST-DONATION TRIPLEX HIV/HCV/HBV NAT IN A TEACHING HOSPITAL TRANSFUSION MEDICINE UNIT IN KUMASI, GHANA * | |
| S. Owusu-Ofori, G. Bedu-Addo, D. Candotti, A. Nsiah-Asare, F. Sarkodie, J-P Allain (Komfo Anokye Teaching Hospital, Kumasi, Ghana) | |
| 13.10 – 13.30 | |
| DISCUSSION | |
| J-P Allain (University of Cambridge, Cambridge,
United Kingdom) * Abstracts to be found in the poster section |
|
Tuesday 5 september 2006
| 13.15 – 14.45 Satellite Symposium organised by Cerus |
Room 1.41 – 1.44 |
| The INTERCEPT Blood System: solving today’s challenges in transfusion safety (Chikungunya virus, protozoa and bacteria) |
|
| Chairs: S. Wendel, E. Seifried | |
| RISK OF TRANSFUSION-TRANSMITTED PARASITIC DISEASE – IS TESTING THE ONLY ANSWER TO TRANSFUSION SAFETY? | |
| S. Wendel (Hospital Sírio Libanes, Sao Paulo, Brazil) | |
| MANAGEMENT OF AN EMERGING PATHOGEN – IMPLEMENTATION OF THE INTERCEPT BLOOD SYSTEM IN FRANCE | |
| J-P Cazenave (Etablissement Français du Sang - Alsace, Strasbourg, France) | |
| BACTERIAL CONTAMINATION OF PLATELET COMPONENTS – TODAY’S SOLUTIONS | |
| E. Seifried (German Red Cross Institute Frankfurt, Frankfurt, Germany) | |
| THE INTERCEPT BLOOD SYSTEM – A HIGHER STANDARD IN BLOOD COMPONENT PROCESS CONTROL AND SAFETY | |
| L. Corash (Cerus Corporation, Concord, United States of America) | |
| 13.15 – 14.45 Satellite Symposium organised by Octapharma |
Room 1.61 – 1.64 |
| FFP or biopharmaceutical Plasma; A Real Therapeutic Dilemma? | |
| OCTAPLAS®: GMP MANUFACTURING - QUALITY AND SAFETY STANDAARD | |
| T-E Svae (Octapharma Pharmazeutika Produktions gmbH, Vienna, Austria) | |
| FFP OR BIOPHARMACEUTICAL PLASMA: HOW TO DECIDE | |
| P. Hellstern (City Hospital. Ludwigshafen, Germany) | |
| ADVERSE REACTIONS OF PLASMA TRANSFUSION; A PARTICULAR CASE: TRALI |
|
| J.H. Sachs (Justus Liebig University Giessen, Giessen, Germany) | |
| EXPERIENCES WITH UNIVERSAL BIOPHARMACEUTICAL PLASMA | |
| C. Rochat (National Bioproducts Institute, Pinetown, South Africa) | |
| SUMMARY | |
| B.. Solheim (Rikshospitalet, Radium Hospitalet, Oslo, Norway) | |
| QUESTIONS | |
| 13:15 – 15.00 Satellite Symposium organised by Chiron |
Ballroom East |
| Impact of individual donation (ID) Nucleic Acid Testing on blood safety |
|
| 13.00 – 13.05 WELCOME AND OPENING | |
| A. Heaton (Chief Medical Officer, Chiron) Introduction of Moderator: Arthur Bird MD. CEO, Western Province Blood Transfusion (WPBTS), Cape Town |
|
| 13.05 – 13.15 BLOOD SAFETY REASONS FOR NAT TESTING IN A SOUTH AFRICAN ENVIRONMENT | |
| A. Heyns (South African National Blood Service, Johannesburg, South Africa) | |
| 13.15 – 13.40 AUTOMATED INDIVIDUAL DONOR NAT TESTING AND ITS IMPLICATIONS FOR POST TRANSFUSION HIV TRANSMISSION RISK IN SOUTH AFRICA | |
| R. Crookes (South African National Blood Service, Johannesburg, South Africa) | |
| 13.40 – 14.05 5 YEARS OF NAT TESTING IN SINGAPORE: TRANSITION FROM SEMI-AUTOMATED HIV/HCV (DUPLEX) TESTING TO AUTOMATED HIV/HCV/HBV (TRIPLEX) TESTING ON TIGRIS | |
| D. Teo (Health Sciences Authority, Singapore, Singapore) | |
| 14.05 – 14.35 HBV WORLDWIDE: POLICY IMPLICATIONS OF NAT DIAGNOSIS AND EPIDEMIOLOGY | |
| B. Carman (West Scotland Specialist Virology Center, Glasgow, Scotland, United Kingdom | |
| 14.35 – 15.00 DISCUSSION ON IMPLICATIONS FOR INTERMEDIATE PREVALENCE COUNTRIES | |
| Moderator: Arthur Bird, Cape Town, South Africa Panel speakers: Kap-No Lee (Korean Red Cross, Seoul, South-Korea), A. Hatzakis (National Retrovirus Reference Center, Athens, Greece) |
|
| 15.00 CLOSURE | |
Wednesday 6 september 2006
| 12.15 – 13.45 Satellite Symposium organised by Roche Molecular Systems |
Room 1.41 – 1.44 |
| Perspectives on Approaches for NAT Automation | |
| NAT AND BLOOD SCREENING | |
| J. Saldanha | |
| COMPARATIVE EVALUATION OF AUTOMATED NAT SYSTEMS: COBAS S 201 SYSTEM (ROCHE) AND TIGRIS SYSTEM (CHIRON) | |
| A. Assal (EFS Centre Atlantique, Tours, France) | |
| WORKFLOW STUDY: EFS EVALUATION OF COBAS S 201 SYSTEM (ROCHE) AND TIGRIS SYSTEM (CHIRON) | |
| V. Barlet (EFS Centre Atlantique, Tours, France) | |
| COBAS S 201 SYSTEM: AUTOMATED BLOOD SCREENING PLATFORM | |
| L. Jarvis (SNBTS, Edinburgh, United Kingdom) | |
| COBAS S 201 BLOOD SCREENING SYSTEM | |
| J. Nunes (Roche Molecular Systems, Pleasanton, United States of America) | |
| 12.15 – 13.45 Satellite Symposium organised by BioRad |
Ballroom West |
| Performance and Cost-Efficiency of HIV and HCV Combo Simultaneous Antigen and Antibody Detection: A Affordable Alternative to N.A.T. in Blood Bank? | |